Cargando…

A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer

Thyroid carcinoma is the most frequent endocrine neoplasia. Different types of thyroid carcinoma are described: well-differentiated papillary thyroid carcinoma (PTC), poorly differentiated thyroid carcinoma (PDTC), follicular thyroid carcinoma (FTC), anaplastic thyroid carcinoma (ATC), and medullary...

Descripción completa

Detalles Bibliográficos
Autores principales: Romei, Cristina, Elisei, Rossella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915177/
https://www.ncbi.nlm.nih.gov/pubmed/33572167
http://dx.doi.org/10.3390/ijms22041726
_version_ 1783657176835817472
author Romei, Cristina
Elisei, Rossella
author_facet Romei, Cristina
Elisei, Rossella
author_sort Romei, Cristina
collection PubMed
description Thyroid carcinoma is the most frequent endocrine neoplasia. Different types of thyroid carcinoma are described: well-differentiated papillary thyroid carcinoma (PTC), poorly differentiated thyroid carcinoma (PDTC), follicular thyroid carcinoma (FTC), anaplastic thyroid carcinoma (ATC), and medullary thyroid carcinoma (MTC). MTC is inherited as an autosomal dominant trait in 25% of cases. The genetic landscape of thyroid carcinoma has been largely deciphered. In PTC, genetic alterations have been found in about 95% of tumors: BRAF mutations and RET rearrangements are the main genetic alterations. BRAF and RAS mutations have been confirmed to play an important role also in PDTC and ATC, together with TP53 mutations that are fundamental in tumor progression. It has also been clearly demonstrated that telomerase reverse transcriptase (TERT) promoter mutations and TP53 mutations are present with a high-frequency in more advanced tumors, frequently associated with other mutations, and their presence, especially if simultaneous, is a signature of aggressiveness. In MTC, next-generation sequencing confirmed that mutations in the RET gene are the most common molecular events followed by H-RAS and K-RAS mutations. The comprehensive knowledge of the genetic events responsible for thyroid tumorigenesis is important to better predict the biological behavior and better plan the therapeutic strategy for specific treatment of the malignancy based on its molecular profile.
format Online
Article
Text
id pubmed-7915177
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79151772021-03-01 A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer Romei, Cristina Elisei, Rossella Int J Mol Sci Review Thyroid carcinoma is the most frequent endocrine neoplasia. Different types of thyroid carcinoma are described: well-differentiated papillary thyroid carcinoma (PTC), poorly differentiated thyroid carcinoma (PDTC), follicular thyroid carcinoma (FTC), anaplastic thyroid carcinoma (ATC), and medullary thyroid carcinoma (MTC). MTC is inherited as an autosomal dominant trait in 25% of cases. The genetic landscape of thyroid carcinoma has been largely deciphered. In PTC, genetic alterations have been found in about 95% of tumors: BRAF mutations and RET rearrangements are the main genetic alterations. BRAF and RAS mutations have been confirmed to play an important role also in PDTC and ATC, together with TP53 mutations that are fundamental in tumor progression. It has also been clearly demonstrated that telomerase reverse transcriptase (TERT) promoter mutations and TP53 mutations are present with a high-frequency in more advanced tumors, frequently associated with other mutations, and their presence, especially if simultaneous, is a signature of aggressiveness. In MTC, next-generation sequencing confirmed that mutations in the RET gene are the most common molecular events followed by H-RAS and K-RAS mutations. The comprehensive knowledge of the genetic events responsible for thyroid tumorigenesis is important to better predict the biological behavior and better plan the therapeutic strategy for specific treatment of the malignancy based on its molecular profile. MDPI 2021-02-09 /pmc/articles/PMC7915177/ /pubmed/33572167 http://dx.doi.org/10.3390/ijms22041726 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Romei, Cristina
Elisei, Rossella
A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer
title A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer
title_full A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer
title_fullStr A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer
title_full_unstemmed A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer
title_short A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer
title_sort narrative review of genetic alterations in primary thyroid epithelial cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915177/
https://www.ncbi.nlm.nih.gov/pubmed/33572167
http://dx.doi.org/10.3390/ijms22041726
work_keys_str_mv AT romeicristina anarrativereviewofgeneticalterationsinprimarythyroidepithelialcancer
AT eliseirossella anarrativereviewofgeneticalterationsinprimarythyroidepithelialcancer
AT romeicristina narrativereviewofgeneticalterationsinprimarythyroidepithelialcancer
AT eliseirossella narrativereviewofgeneticalterationsinprimarythyroidepithelialcancer